Vivos Stock Performance

VVOS -  USA Stock  

USD 2.65  0.10  3.64%

The entity has a beta of 1.0339, which indicates a somewhat significant risk relative to the market. Let's try to break down what Vivos's beta means in this case. Vivos Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Vivos Therapeutics is expected to follow. Even though it is essential to pay attention to Vivos Therapeutics current price movements, it is always good to be careful when utilizing equity historical returns. Our philosophy towards measuring any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Vivos Therapeutics exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Vivos Therapeutics has an expected return of -0.93%. Please be advised to validate Vivos Therapeutics treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price to decide if Vivos Therapeutics performance from the past will be repeated at some point in the near future.

Vivos Stock Performance 

 
Refresh
Vivos Performance
0 of 100
Over the last 90 days Vivos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2021. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more

Vivos Price Channel

Quick Ratio4.04
Fifty Two Week Low2.4900
Target High Price12.00
Fifty Two Week High14.4100
Target Low Price10.00

Vivos Therapeutics Relative Risk vs. Return Landscape

If you would invest  523.00  in Vivos Therapeutics on August 30, 2021 and sell it today you would lose (258.00)  from holding Vivos Therapeutics or give up 49.33% of portfolio value over 90 days. Vivos Therapeutics is currently does not generate positive expected returns and assumes 4.5948% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Vivos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Vivos Therapeutics is expected to under-perform the market. In addition to that, the company is 6.13 times more volatile than its market benchmark. It trades about -0.2 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.03 per unit of volatility.

Vivos Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Vivos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vivos Therapeutics, and traders can use it to determine the average amount a Vivos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.2031

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsVVOS
Estimated Market Risk
 4.59
  actual daily
 
 39 %
of total potential
 
3939
Expected Return
 -0.93
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.2
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Vivos Therapeutics is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vivos Therapeutics by adding it to a well-diversified portfolio.

About Vivos Therapeutics Performance

To evaluate Vivos Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Vivos Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Vivos Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Vivos Therapeutics stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Vivos's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea . Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado. Vivos Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.

Things to note about Vivos Therapeutics

Checking the ongoing alerts about Vivos Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Vivos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Vivos Therapeutics Alerts

Equity Alerts and Improvement Suggestions

Vivos Therapeutics generated a negative expected return over the last 90 days
Vivos Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 14.54 M. Net Loss for the year was (20.94 M) with profit before overhead, payroll, taxes, and interest of 10.41 M.
Vivos Therapeutics currently holds about 34.2 M in cash with (11.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.5.
Roughly 22.0% of the company outstanding shares are owned by insiders
Latest headline from www.equities.com: Vivos falls 0.77 percent to Close at 3.87 on November 2 - Equities.com
Also, please take a look at World Market Map. Note that the Vivos Therapeutics information on this page should be used as a complementary analysis to other Vivos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Vivos Stock analysis

When running Vivos Therapeutics price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Is Vivos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vivos Therapeutics. If investors know Vivos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vivos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vivos Therapeutics is measured differently than its book value, which is the value of Vivos that is recorded on the company's balance sheet. Investors also form their own opinion of Vivos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vivos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vivos Therapeutics' market value can be influenced by many factors that don't directly affect Vivos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vivos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Vivos Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vivos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.